Journal
CANCER AND METASTASIS REVIEWS
Volume 37, Issue 4, Pages 719-731Publisher
SPRINGER
DOI: 10.1007/s10555-018-9763-8
Keywords
Osteosarcoma; Metastasis; Metabolomics; ncRNA; Clinical trial
Categories
Funding
- Department of Orthopaedic Surgery at UCLA
- Sarcoma Foundation of America (SFA)
- National Cancer Institute (NCI)/National Institutes of Health (NIH) [UO1, CA151452-01]
Ask authors/readers for more resources
Although the investigation into biomarkers specific for pulmonary metastasis within osteosarcoma (OS) has recently expanded, their usage within the clinic remains sparse. The current screening protocol after any OS diagnosis includes a chest CT scan; however, metastatic lung nodules frequently go undetected and remain the primary cause of death in OS. Recently, screening technologies such as liquid biopsy and next-generation sequencing have revealed a promising array of biomarkers with predictive and diagnostic value for the pulmonary metastasis associated with OS. These biomarkers draw from genomics, transcriptomics, epigenetics, and metabolomics. When assessed in concert, their utility is most promising as OS is a highly heterogeneous cancer. Accordingly, there has been an expansion of clinical trials not only aimed at further demonstrating the significance of these individual biomarkers but to also reveal which therapies resolve the pulmonary metastasis once detected. This review will focus on the recently discovered and novel metastatic biomarkers within OS, their molecular and cellular mechanisms, the expansion of humanized OS mouse models amenable to their testing, and the associated clinical trials aimed at managing the metastatic phase of OS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available